Zydus Lifesciences receives EIR for its API manufacturing facility at Ambernath
Zydus Lifesciences has received the EIR report from the USFDA for
the inspection conducted at its API manufacturing facility located at Ambernath, Maharashtra.
This facility underwent an inspection from 10 to 14 February 2025, and had ended with NIL observations. The EIR report has classified it as No Action Indicated (NAI).
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: May 14 2025 | 3:28 PM IST